Effects of Photobiomodulation Therapy Combined with Static Magnetic Field in Severe COVID-19 Patients Requiring Intubation: A Pragmatic Randomized Placebo-Controlled Trial

被引:18
|
作者
De Marchi, Thiago [1 ,2 ]
Francio, Fabiano [1 ,3 ]
Ferlito, Joao Vitor [3 ]
Weigert, Renata [3 ]
de Oliveira, Cristiane [3 ]
Merlo, Ana Paula [3 ]
Pandini, Delcio Luis [3 ]
Pasqual-Junior, Bolivar Antonio [3 ]
Giovanella, Daniela [3 ]
Tomazoni, Shaiane Silva [4 ,5 ]
Leal-Junior, Ernesto Cesar [2 ,4 ,5 ]
机构
[1] Univ Ctr Bento Goncalves UNICNEC, Bento Goncalves, RS, Brazil
[2] Nove Julho Univ, Lab Phototherapy & Innovat Technol Hlth LaPIT, Postgrad Program Rehabil Sci, Sao Paulo, Brazil
[3] Hosp Tacchini, Bento Goncalves, RS, Brazil
[4] Univ Bergen, Dept Global Publ Hlth & Primary Care, Physiotherapy Res Grp, Blokk D,Arstadveien 17, NO-5020 Bergen, Norway
[5] Sci Consultants, ELJ Consultancy, Sao Paulo, Brazil
关键词
COVID-19; photobiomodulation; intensive care unit; respiratory muscles; ventilatory parameters; mechanical ventilation; LEVEL LASER THERAPY; MECHANICAL VENTILATION; MUSCLE; INFLAMMATION; PERFORMANCE; IMPROVEMENT; PNEUMONIA; EXERCISE; PBMT; RED;
D O I
10.2147/JIR.S318758
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose: We aimed to investigate the effects of photobiomodulation therapy combined with static magnetic field (PBMT-sMF) on the length of intensive care unit (ICU) stay and mortality rate of severe COVID-19 patients requiring invasive mechanical ventilation and assess its role in preserving respiratory muscles and modulating inflammatory processes. Patients and Methods: We conducted a prospectively registered, triple-blinded, randomized, placebo-controlled trial of PBMT-sMF in severe COVID-19 ICU patients requiring invasive mechanical ventilation. Patients were randomly assigned to receive either PBMT-sMF or a placebo daily throughout their ICU stay. The primary outcome was length of ICU stay, defined by either discharge or death. The secondary outcomes were survival rate, diaphragm muscle function, and the changes in blood parameters, ventilatory parameters, and arterial blood gases. Results: Thirty patients were included and equally randomized into the two groups. There were no significant differences in the length of ICU stay (mean difference, MD = -6.80; 95% CI = -18.71 to 5.11) between the groups. Among the secondary outcomes, significant differences were observed in diaphragm thickness, fraction of inspired oxygen, partial pressure of oxygen/fraction of inspired oxygen ratio, C-reactive protein levels, lymphocyte count, and hemoglobin (p < 0.05). Conclusion: Among severe COVID-19 patients requiring invasive mechanical ventilation, the length of ICU stay was not significantly different between the PBMT-sMF and placebo groups. In contrast, PBMT-sMF was significantly associated with reduced diaphragm atrophy, improved ventilatory parameters and lymphocyte count, and decreased C-reactive protein levels and hemoglobin count.
引用
收藏
页码:3569 / 3585
页数:17
相关论文
共 50 条
  • [41] Efficacy of the adjunctive use of photobiomodulation therapy in olfactory disorders in post-COVID-19 patients: A randomized controlled trial
    Oliveira, Patricia Costa
    Correia, Luisa Oliveira
    Lopes, Natalia Medeiros Dias
    Suassuna, Gabriel Rodrigues
    Doty, Richard L.
    Pinna, Fabio de Rezende
    Voegels, Richard Louis
    Fornazieri, Marco Aurelio
    BRAZILIAN JOURNAL OF OTORHINOLARYNGOLOGY, 2025, 91 (04)
  • [42] Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial
    Lopes, Maria Isabel
    Bonjorno, Leticia P.
    Giannini, Marcela C.
    Amaral, Natalia B.
    Menezes, Pamella Indira
    Dib, Saulo Musse
    Gigante, Samara Libich
    Benatti, Maira N.
    Rezek, Uebe C.
    Emrich-Filho, Laerte L.
    Sousa, Betania A. A.
    Almeida, Sergio C. L.
    Luppino Assad, Rodrigo
    Veras, Flavio P.
    Schneider, Ayda
    Rodrigues, Tamara S.
    Leiria, Luiz O. S.
    Cunha, Larissa D.
    Alves-Filho, Jose C.
    Cunha, Thiago M.
    Arruda, Eurico
    Miranda, Carlos H.
    Pazin-Filho, Antonio
    Auxiliadora-Martins, Maria
    Borges, Marcos C.
    Fonseca, Benedito A. L.
    Bollela, Valdes R.
    Del-Ben, Cristina M.
    Cunha, Fernando Q.
    Zamboni, Dario S.
    Santana, Rodrigo C.
    Vilar, Fernando C.
    Louzada-Junior, Paulo
    Oliveira, Rene D. R.
    RMD OPEN, 2021, 7 (01):
  • [43] Effect of Crizanlizumab, a P-Selection inhibitor, in COVID-19 A Placebo-Controlled, Randomized Trial
    Leucker, Thorsten M.
    Osburn, William O.
    Reventun, Paula
    Smith, Kimberley
    Claggett, Brian
    Kirwan, Bridget-Anne
    de Brouwer, Sophie
    Williams, Marlene S.
    Gerstenblith, Gary
    Hager, David N.
    Streiff, Michael B.
    Solomon, Scott D.
    Lowenstein, Charles J.
    JACC-BASIC TO TRANSLATIONAL SCIENCE, 2021, 6 (12): : 935 - 945
  • [44] Effects of photobiomodulation therapy in patients with chronic non-specific low back pain: protocol for a randomised placebo-controlled trial
    Tomazoni, Shaiane Silva
    Menezes Costa, Luciola da Cunha
    Guimaraes, Layana de Souza
    Araujo, Amanda Costa
    Nascimento, Dafne Port
    de Medeiros, Flavia Cordeiro
    Avanzi, Marina Athayde
    Pena Costa, Leonardo Oliveira
    BMJ OPEN, 2017, 7 (10):
  • [45] Amantadine in unvaccinated patients with early, mild to moderate COVID-19: A randomized, placebo-controlled, double-blind trial
    Rejdak, Konrad
    Fiedor, Piotr
    Bonek, Robert
    Lukasiak, Jacek
    Chelstowski, Waldemar
    Kiciak, Slawomir
    Dabrowski, Piotr
    Gala-Bladzinska, Agnieszka
    Dec, Mateusz
    Papuc, Ewa
    Zasybska, Adriana
    Kaczor, Marcin
    Grieb, Pawel
    EUROPEAN JOURNAL OF NEUROLOGY, 2024, 31 (01)
  • [46] Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial
    Boesing, Maria
    Abig, Kristin
    Brandle, Michael
    Brutsche, Martin
    Burri, Emanuel
    Frye, Bjoern C.
    Giezendanner, Stephanie
    Grutters, Jan C.
    Haas, Philippe
    Heisler, Justian
    Jaun, Fabienne
    Leuppi-Taegtmeyer, Anne B.
    Luthi-Corridori, Giorgia
    Mueller-Quernheim, Joachim
    Nuesch, Reto
    Pohl, Wolfgang
    Rassouli, Frank
    Leuppi, Jorg D.
    TRIALS, 2022, 23 (01)
  • [47] Annexin A5 in Patients With Severe COVID-19 Disease: A Single-Center, Randomized, Double-Blind, Placebo-Controlled Feasibility Trial
    Martin, Claudio M.
    Slessarev, Marat
    Campbell, Eileen
    Basmaji, John
    Ball, Ian
    Fraser, Douglas D.
    Leligdowicz, Aleksandra
    Mele, Tina
    Priestap, Fran
    Tschirhart, Brent J.
    Bentall, Tracey
    Lu, Xiangru
    Feng, Qingping
    CRITICAL CARE EXPLORATIONS, 2023, 5 (10) : E0986
  • [48] Peginterferon lambda for the treatment of hospitalized patients with mild COVID-19: A pilot phase 2 randomized placebo-controlled trial
    Kim, Myung-Ho
    Elbaz, Josh
    Jilg, Nikolaus
    Gustafson, Jenna L.
    Xu, Min
    Hatipoglu, Dilara
    Nohelty, Eric
    Kim, Arthur Y.
    Chung, Raymond T. T.
    FRONTIERS IN MEDICINE, 2023, 10
  • [49] Ozanimod Therapy in Patients With COVID-19 Requiring Oxygen Support A Randomized Open-Label Pilot Trial
    Lellouche, Francois
    Blais-Lecours, Pascale
    Maltais, Francois
    Sarrazin, Jean-Francois
    Rola, Philippe
    Nguyen, Tuyen
    Chateauvert, Nathalie
    Marsolais, David
    CHEST, 2024, 165 (04) : 810 - 819
  • [50] Atovaquone for treatment of COVID-19: A prospective randomized, double-blind, placebo-controlled clinical trial
    Jain, Mamta K.
    De Lemos, James A.
    McGuire, Darren K.
    Ayers, Colby.
    Eitson, Jennifer L.
    Sanchez, Claudia L.
    Kamel, Dena
    Meisner, Jessica A.
    Thomas, Emilia V.
    Hegde, Anita A.
    Mocherla, Satish
    Strebe, Joslyn K.
    Li, Xilong
    Williams, Noelle S.
    Xing, Chao
    Ahmed, Mahmoud S.
    Wang, Ping
    Sadek, Hesham A.
    Schoggins, John W.
    FRONTIERS IN PHARMACOLOGY, 2022, 13